Key Takeaways
How to Get Out of Depression: What Recovery Looks Like in Studies
In research terms, how to get out of depression is a question about three milestones: an episode ends, the improvement holds, and a new episode does not follow. Most episodes do end. In a Dutch population study of new-onset major depressive episodes, half of people had recovered within 3 months and 76% within 12 months[1].
Nearly 20% of that group had not recovered at 24 months[1]. U.S. prevalence figures and trends are on the depression page, and the diagnosis itself on the major depressive disorder page.
Everyday strategies such as exercise, activity scheduling and sleep routines are covered in how to deal with depression. This article covers the clinical path out: how long episodes last, how improvement is measured, what happens when treatment stalls, and what predicts staying well.
Thoughts of suicide are an emergency rather than a recovery-timeline question. The 988 Suicide & Crisis Lifeline takes calls and texts at 988.
Response, Remission and Recovery: What Getting Out Means
Clinicians split improvement into stages. The 2022 VA/DoD guideline defines a response to treatment as a PHQ-9 score improvement of at least 50% from baseline[3].
Remission is a PHQ-9 score of 4 or less maintained for at least one month, and recovery is the same score maintained for at least six months[3]. A new episode after remission is a recurrence[3].
The distinction matters because improving is not the same as returning to baseline. The guideline notes that many patients continue to have residual subsyndromal symptoms, and that in a minority an episode persists for over two years and is defined as chronic[3]. Long-running depression is covered on the persistent depressive disorder page.
Remission (depression)
A period in which depressive symptoms fall to minimal levels. The VA/DoD guideline defines it as a PHQ-9 score of 4 or less maintained for at least one month; the same score held for at least six months counts as recovery[3].
Related Terms
Source: VA/DoD Clinical Practice Guideline for MDD, 2022
Stages of Improvement as Defined by the VA/DoD Guideline
| Stage | Definition | Must last |
|---|---|---|
| Partial response | Less than 50% improvement in symptoms | Not specified |
| Response | PHQ-9 improves 50% or more from baseline | Not specified |
| Remission | PHQ-9 score of 4 or less | At least 1 month |
| Recovery | PHQ-9 score of 4 or less | At least 6 months |
| Recurrence | A new major depressive episode after remission | Not applicable |
Definitions from the VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder, version 4.0, 2022[3].
1PHQ-9 scores range from 0 to 27; higher scores mean more severe symptoms.
Sources
- •VA/DoD, 2022
How Long Does It Take to Get Out of Depression?
In the first NEMESIS study, which surveyed 7,076 Dutch adults, the median duration of a new major depressive episode was 3.0 months[1]. Recovery reached 63% by 6 months and 76% by 12 months[1].
The follow-up cohort, NEMESIS-2, found longer episodes: a median of 6 months and a mean of 10.7 months[2]. In that study, 12% of people with major depression had not recovered at 36 months, which pulls the average well above the median[2].
Both studies sampled the general population rather than clinics, so they include mild episodes and people who never sought care[1][2]. The data are Dutch, and the first study is from 2002, so U.S. timelines may differ[1].
What predicts a longer episode
In NEMESIS, more severe depression and comorbid dysthymia predicted a longer episode, while a recurrent episode predicted a shorter one[1]. In NEMESIS-2, longer duration was associated with comorbid dysthymia, anxiety disorder and psychotropic medication use[2].
The medication finding is an association from an observational study. It cannot show whether medication users simply had more severe episodes to begin with.
How Long Major Depressive Episodes Lasted in Two Population Studies
| Measure | NEMESIS (2002) | NEMESIS-2 (2017) |
|---|---|---|
| Median duration | 3.0 months | 6 months |
| Mean duration | 8.4 months | 10.7 months |
| Recovered within 6 months | 63% | Not reported |
| Recovered within 12 months | 76% | Not reported |
| Not recovered at end of follow-up | Nearly 20% at 24 months | 12% at 36 months |
Duration of major depressive episodes in Dutch general-population cohorts. NEMESIS tracked newly originated episodes over 2 years[1]; NEMESIS-2 followed episodes over 3 years[2].
1The NEMESIS mean was calculated with a 24-month upper limit[1].
Sources
- •Spijker et al., 2002
- •ten Have et al., 2017
Share of new major depressive episodes that had ended within 12 months, Dutch general population
Half recovered within 3 months, but nearly 1 in 5 were still depressed at 24 months. That slower group is the focus of most treatment research.
"76% within 12 months and nearly 20% had not recovered at 24 months"
The Treatment Route: Therapy, Medication and Tracking Progress
NIMH describes depression treatment as psychotherapy, medication or both, with brain stimulation therapy as an option when those do not reduce symptoms enough[4]. For milder depression, psychotherapy is often tried first, while people with moderate or severe depression are usually prescribed medication as part of the initial plan[4].
Cognitive behavioral therapy (CBT) and interpersonal therapy (IPT) are the evidence-based psychotherapies NIMH names[4]. Trial results are covered in cognitive behavioral therapy for depression and anti-depression meds.
Antidepressants usually take 4 to 8 weeks to work, and sleep, appetite and concentration often improve before mood lifts[4]. NIMH notes that finding the best treatment may take trial and error[4].
Why progress is measured
The VA/DoD guideline calls for monitoring at least monthly after a treatment starts or changes, to track response[3]. The questionnaire it uses is explained in PHQ-9 depression test.
Early change carries information. A meta-analysis of 41 antidepressant trials with 6,562 patients found that at least 20% improvement within 2 weeks predicted later stable response and stable remission with high sensitivity (at least 81% and 87%)[5].
The absence of early change was the stronger signal: negative predictive values ranged from 82% to 100%, meaning stable remission was unlikely without improvement by week 2[5]. All 41 trials compared mirtazapine with other drugs or placebo, which limits how far the finding generalizes[5].
What Happens When the First Treatment Does Not Work?
STAR*D, a study at 41 North American psychiatry and primary care centers that enrolled 4,041 adults, offered up to four treatment steps in sequence[7]. Self-rated remission rates were 36.8% at step 1, 30.6% at step 2, 13.7% at step 3 and 13.0% at step 4, for a reported cumulative remission rate of 67%[6].
That 67% figure has been challenged: a 2023 reanalysis of the patient-level data, using the protocol's blinded Hamilton scale and dropping patients who should have been excluded, found a cumulative remission rate of 35.0%[7].
In STAR*D's own data, each later step helped fewer people[6]. Participants who needed more steps also had higher relapse rates during follow-up, whether or not they had reached remission[6].
Treatment-resistant depression
NIMH defines treatment-resistant depression as not getting better after trying at least two antidepressants[4]. Options it lists include esketamine, an FDA-approved nasal spray given in a clinical setting, and adding a different type of medication such as an antipsychotic or anticonvulsant[4].
The most used brain stimulation therapies are electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS)[4]. They are covered in electric shock therapy and TMS treatment for depression, and the condition on the treatment-resistant depression page.
Staying Out: Residual Symptoms, Relapse and Recurrence
How fully an episode ends is linked to how long recovery lasts. In a prospective study of 237 patients, those who recovered with residual subthreshold symptoms relapsed to their next major episode more than 3 times faster than those who recovered without symptoms[8].
The same group relapsed to any depressive episode more than 5 times faster, a median of 33 weeks compared with 184 weeks[8]. The VA/DoD definitions reflect the same point: remission requires a near-minimal PHQ-9 score of 4 or less, not just a 50% drop[3].
Recurrence risk depends heavily on the setting. A 2010 systematic review found recurrence of 60% after 5 years, 67% after 10 years and 85% after 15 years in specialized mental health care, compared with 35% after 15 years in the general population[10].
That review named the number of previous episodes and subclinical residual symptoms as the most important predictors of recurrence[10]. A later Dutch cohort of 746 remitted adults reported lower figures: 4.3% at 5 years, 13.4% at 10 years and 27.1% at 20 years[11].
In that cohort, earlier recurrence was predicted by previous episodes, severity, childhood abuse, negative life events and psychiatric comorbidity, among other factors[11].
Continuing or stopping medication
In the UK ANTLER trial, 478 primary care patients who felt well enough to stop antidepressants were randomized to continue or discontinue[9]. By 52 weeks, 39% of the maintenance group and 56% of the discontinuation group had relapsed, a hazard ratio of 2.06[9].
NIMH advises talking to a health care provider before starting or stopping any medication[4]. Psychological relapse prevention, including mindfulness-based cognitive therapy, is summarized in how to deal with depression.
Where the Recovery Evidence Is Thin
The best duration data come from Dutch general-population cohorts, not U.S. samples[1][2]. The two cohorts disagree on the median episode length, 3.0 months versus 6 months, which shows how much the estimate depends on sample and method[1][2].
STAR*D was open label and semi-randomized, so it was not designed to separate drug effects from natural recovery over time[7]. Its headline remission figure also depends on which rating scale is used, as the 2023 reanalysis showed[7].
The two-week early-improvement finding comes from trials of a single drug, mirtazapine, against comparators[5]. ANTLER enrolled only UK primary care patients who already felt well enough to stop their medication[9].
Recurrence estimates range from 27.1% over 20 years in a population cohort to 85% over 15 years in specialized care[10][11]. Any single figure therefore describes a particular group, not every person recovering from depression.
Frequently Asked Questions
Sources & References
- Spijker J, de Graaf R, Bijl RV, Beekman ATF, Ormel J, Nolen WA. Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). The British Journal of Psychiatry. Published 2002. Accessed October 2026. https://doi.org/10.1192/bjp.181.3.208 [Link]
- ten Have M, Penninx BWJH, Tuithof M, et al. Duration of major and minor depressive episodes and associated risk indicators in a psychiatric epidemiological cohort study of the general population. Acta Psychiatrica Scandinavica. Published 2017. Accessed October 2026. https://doi.org/10.1111/acps.12753 [Link]
- U.S. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder: Provider Summary, Version 4.0. U.S. Department of Veterans Affairs and Department of Defense. Published 2022. Accessed October 2026. https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPG_ProviderSummary_Final_508_updated.pdf [Link]
- National Institute of Mental Health. Depression. National Institutes of Health. Published 2024. Accessed October 2026. https://www.nimh.nih.gov/health/publications/depression [Link]
- Szegedi A, Jansen WT, van Willigenburg APP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. Journal of Clinical Psychiatry. Published 2009. Accessed October 2026. https://doi.org/10.4088/JCP.07m03780 [Link]
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry. Published 2006. Accessed October 2026. https://doi.org/10.1176/ajp.2006.163.11.1905 [Link]
- Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research protocol. BMJ Open. Published 2023. Accessed October 2026. https://bmjopen.bmj.com/content/13/7/e063095 [Link]
- Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of Affective Disorders. Published 1998. Accessed October 2026. https://doi.org/10.1016/S0165-0327(98)00138-4 [Link]
- Lewis G, Marston L, Duffy L, et al. Maintenance or discontinuation of antidepressants in primary care. New England Journal of Medicine. Published 2021. Accessed October 2026. https://doi.org/10.1056/NEJMoa2106356 [Link]
- Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman ATF. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatrica Scandinavica. Published 2010. Accessed October 2026. https://doi.org/10.1111/j.1600-0447.2009.01519.x [Link]
- ten Have M, de Graaf R, van Dorsselaer S, et al. Recurrence and chronicity of major depressive disorder and their risk indicators in a population cohort. Acta Psychiatrica Scandinavica. Published 2018. Accessed October 2026. https://doi.org/10.1111/acps.12874 [Link]